Development of radioactive ‘tracer’ paves the way for hospital scan to detect changes in lung before any secondary tumours are visible.

Wednesday 16 August 2017      Latest research Our research
Scientist looking at a screening image on a computer screen

Scientists part-funded by Breast Cancer Now, the Medical Research Council (MRC) and other collaborators have developed an innovative imaging technique that could predict whether breast cancer will spread to the lung.

In a new study published in Theranostics, researchers have demonstrated in mice that a new non-invasive imaging method can be used to detect changes in the lungs that signal breast cancer may soon spread there – before any metastases are visible.

If validated in humans, this approach could enable patients to be offered more intensive therapy earlier, to potentially prevent breast cancer spread.

Previous research has shown that the gathering of a special type of immune cell called ‘myeloid-derived suppressor cells’ (MDSCs) – in locations such as the lung – prepares the ground for breast cancer metastasis, by suppressing the local immune system and promoting the formation of new blood vessels (angiogenesis).

Researchers at King’s College London – in collaboration with teams at University College London and the University Hospital Muenster in Germany – have now developed a radioactive ‘tracer’ molecule to detect MDSCs accumulating in the lung in preparation for the arrival of breast cancer cells and the formation of metastases.

MDSCs are known to release a protein duo ‘message’ called S100A8/A9 which instructs the cells to gather in the lungs. The gathering of these MDSCs in the lung causes inflammation, which makes it a favourable location for cancer cells to metastasise to.

The research teams – led by Dr Michel Eisenblätter and Dr Fabian Flores-Borja at King’s College London – hypothesised that, by making S100A8/A9 visible, it could be possible to identify when the lungs were being prepared for colonisation by breast cancer cells.

To test this theory, they developed a ‘tracer’ antibody able to attach itself to S100A8/A9, that can be detected using a special scan called SPECT (single photon emission computed tomography) – a 3D gamma-ray scanner. The tracer releases radiation which can be distinguished by the SPECT scanner, highlighting areas where S100A8/A9 molecules, and MDSCs, are accumulating.

The researchers tested the tracer with triple negative breast cancer cells that had been implanted in mice, and were able to show – using a miniature SPECT scanner – that the ‘tracer’ lit up the lungs of mice well before any tumour cells were visible in the lung.

SPECT scan showing the radioactive tracer ‘lighting up’ the lungs

SPECT scan showing the radioactive tracer ‘lighting up’ the lungs where special immune cells (MDSCs) are accumulating, priming the lungs for the arrival of migrating breast cancer cells and formation of secondary tumours. The left set of images show the lungs of mice without breast cancer, and the right set shows the lungs of mice which had been injected with aggressive breast cancer cells. Image credit: M. Eisenblaetter, F. Flores-Borja, et al. Available via Open Access online.

Furthermore, the tracer could distinguish between highly aggressive breast cancer with a high tendency to spread to the lung and tumours without metastatic potential.

Currently, to assess the risk of a patient’s breast cancer spreading, doctors use tools based upon the features of the primary tumour, such as tumour size and whether it has already invaded nearby lymph nodes.

With this early-stage study demonstrating the technique to be effective in mice, further studies are now required to develop a more effective ‘tracer’ molecule – better suited for use in humans – to be tested in clinical trials in future.

Dr Fabian Flores-Borja, Research Fellow at the Breast Cancer Now Research Unit at King’s College London:

“By combining cell biology and imaging techniques, we have established a method to predict, at an early time-point during tumour development, whether tumour invasion will occur.

“We envision this technique being used to help select patients for either further surveillance or intensified therapy, as well as aiding cancer research.

“The development of a test that is able to identify an increased risk of metastasis soon after a patient is diagnosed with breast cancer, would be very useful in helping choose the best treatment for patients.”

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, which helped fund the study, said:

“While more research is needed before this could be tested in patients, the prospect of a hospital scan which could predict whether breast cancer will spread to the lungs is incredibly exciting.

“More immediately, this study brings a brand-new method to the table that will help researchers unpick how the immune system is involved in the spread of breast cancer. Finding ways to predict and halt the spread of the disease will be crucial if we are to finally stop people dying from it.

“This is a promising step towards being able to use 3D imaging to help offer more personalised therapy. Ultimately, anything that could provide patients and their doctors with a more accurate picture of whether their breast cancer may spread will help us tailor treatments to stop this from happening.”

Dr Mariana Delfino-Machin, MRC Programme Manager for Cancer, said:

“This study in mice has demonstrated that immune cells can be used as a warning system for breast cancer metastasis in the lungs, and it paves the way towards developing a similar warning system for use in the clinic.

“Innovative, non-invasive imaging methods like this, which can help predict and diagnose disease as early as possible and avoid the discomfort of current invasive tests, have the potential to greatly impact cancer treatment and outcomes. This promising, early-stage study is a great example of the kind of cancer research that the MRC proudly supports.”

This work was also supported by the Medical Research Council, the National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, KCL and UCL Comprehensive Cancer Imaging Centre, the German Research Foundation, Cancer Research UK, and the Engineering and Physical Sciences Research Council (EPSRC). The SPECT scanning equipment at KCL was funded by the Wellcome Trust.

Breast Cancer Now thanks the Sarah Greene Tribute Fund and Walk the Walk for their generous support of this research at the Breast Cancer Now Research Unit at King’s College London.